Positive News SentimentPositive NewsNASDAQ:XERS Xeris Biopharma (XERS) Stock Forecast, Price & News $2.82 +0.20 (+7.63%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$2.63▼$2.8250-Day Range$1.27▼$2.9552-Week Range$0.97▼$3.03Volume819,559 shsAverage VolumeN/AMarket Capitalization$382.19 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Xeris Biopharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside77.3% Upside$5.00 Price TargetShort InterestBearish6.15% of Shares Sold ShortDividend StrengthN/ASustainability-1.57Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.47) to ($0.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.05 out of 5 starsMedical Sector465th out of 983 stocksPharmaceutical Preparations Industry221st out of 486 stocks 3.5 Analyst's Opinion Consensus RatingXeris Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Xeris Biopharma has a forecasted upside of 77.3% from its current price of $2.82.Amount of Analyst CoverageXeris Biopharma has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.15% of the outstanding shares of Xeris Biopharma have been sold short.Short Interest Ratio / Days to CoverXeris Biopharma has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Xeris Biopharma has recently decreased by 1.88%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldXeris Biopharma does not currently pay a dividend.Dividend GrowthXeris Biopharma does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreXeris Biopharma has received a 62.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Pancreatic hormones (H04)" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Xeris Biopharma is -1.57. Previous Next 2.5 News and Social Media Coverage News SentimentXeris Biopharma has a news sentiment score of 1.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Xeris Biopharma this week, compared to 2 articles on an average week.Search InterestOnly 15 people have searched for XERS on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Xeris Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xeris Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.36% of the stock of Xeris Biopharma is held by insiders.Percentage Held by InstitutionsOnly 0.12% of the stock of Xeris Biopharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Xeris Biopharma are expected to grow in the coming year, from ($0.47) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xeris Biopharma is -4.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xeris Biopharma is -4.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXeris Biopharma has a P/B Ratio of 12.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Xeris Biopharma (NASDAQ:XERS) StockXeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.Read More Receive XERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address XERS Stock News HeadlinesJune 1, 2023 | finance.yahoo.comXeris Biopharma to Participate at the Jefferies Healthcare ConferenceMay 14, 2023 | americanbankingnews.comHC Wainwright Research Analysts Boost Earnings Estimates for Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)June 4, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 13, 2023 | americanbankingnews.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Forecasted to Earn FY2026 Earnings of $0.15 Per ShareMay 12, 2023 | americanbankingnews.comQ2 2023 Earnings Forecast for Xeris Biopharma Holdings, Inc. Issued By SVB Leerink (NASDAQ:XERS)May 11, 2023 | msn.comHC Wainwright & Co. Reiterates Xeris Biopharma Holdings (XERS) Buy RecommendationMay 11, 2023 | markets.businessinsider.comXeris Pharmaceuticals (XERS) Gets a Buy from H.C. WainwrightMay 9, 2023 | finance.yahoo.comQ1 2023 Xeris Biopharma Holdings Inc Earnings CallJune 4, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 9, 2023 | proactiveinvestors.comNews snapshot: Delta 9 Cannabis, FansUnite, Vivos Therapeutics, Xeris Biopharma, Givex...May 9, 2023 | proactiveinvestors.comXeris Biopharma posts record revenue in 1QMay 9, 2023 | finance.yahoo.comXeris Biopharma Reports First Quarter 2023 Financial ResultsMay 8, 2023 | finance.yahoo.comXeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are individual investors with 56% stake, while 33% is held by institutionsMay 8, 2023 | americanbankingnews.comXeris Biopharma (XERS) Set to Announce Earnings on TuesdayMay 2, 2023 | finance.yahoo.comXeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023April 18, 2023 | proactiveinvestors.comXeris Biopharma secures US patent for XeriSol formulationsApril 18, 2023 | finance.yahoo.comXeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ FormulationsApril 17, 2023 | finance.yahoo.comSubdued Growth No Barrier To Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) With Shares Advancing 61%April 9, 2023 | americanbankingnews.comContrasting Xeris Biopharma (NASDAQ:XERS) & Capricor Therapeutics (NASDAQ:CAPR)April 6, 2023 | finance.yahoo.comStrong week for Xeris Biopharma Holdings (NASDAQ:XERS) shareholders doesn't alleviate pain of one-year lossMarch 31, 2023 | americanbankingnews.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Short Interest UpdateMarch 30, 2023 | proactiveinvestors.comXeris Biopharma announces research evaluation collaboration and option agreement with Regeneron for XeriJectMarch 30, 2023 | finance.yahoo.comXeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™March 29, 2023 | proactiveinvestors.comXeris Biopharma appoints brand management expert Ricki Fairley to its board of directorsMarch 29, 2023 | finance.yahoo.comXeris Biopharma Appoints Ricki Fairley to Board of DirectorsMarch 10, 2023 | proactiveinvestors.comXeris Biopharma shares 2023 financial guidance after positive year end and fourth quarter resultsMarch 9, 2023 | finance.yahoo.comQ4 2022 Xeris Biopharma Holdings Inc Earnings CallSee More Headlines XERS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XERS Company Calendar Last Earnings3/08/2023Today6/04/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XERS CUSIPN/A CIK1867096 Webwww.xerispharma.com Phone(844) 445-5704FaxN/AEmployees294Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.00 High Stock Price Forecast$6.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+77.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,660,000.00 Net Margins-64.08% Pretax Margin-64.92% Return on Equity-147.04% Return on Assets-23.32% Debt Debt-to-Equity Ratio6.24 Current Ratio2.03 Quick Ratio1.68 Sales & Book Value Annual Sales$110.25 million Price / Sales3.47 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book12.82Miscellaneous Outstanding Shares135,530,000Free Float129,622,000Market Cap$382.19 million OptionableNot Optionable BetaN/A Social Links Key ExecutivesPaul R. EdickChairman & Chief Executive OfficerJohn Patrick ShannonPresident & Chief Operating OfficerSteven M. PieperChief Financial OfficerSteven PrestrelskiChief Scientific OfficerKen JohnsonSenior VP-Clinical Development & Medical AffairsKey CompetitorsAtea PharmaceuticalsNASDAQ:AVIRNuvation BioNYSE:NUVBVanda PharmaceuticalsNASDAQ:VNDAVera TherapeuticsNASDAQ:VERAApollomicsNASDAQ:APLMView All CompetitorsInstitutional OwnershipProShare Advisors LLCBought 25,011 shares on 5/26/2023Ownership: 0.018%JPMorgan Chase & Co.Bought 671,873 shares on 5/18/2023Ownership: 0.565%New York State Common Retirement FundSold 69,700 shares on 5/18/2023Ownership: 0.017%Jane Street Group LLCSold 45,740 shares on 5/16/2023Ownership: 0.100%AQR Capital Management LLCSold 18,688 shares on 5/16/2023Ownership: 0.023%View All Institutional Transactions XERS Stock - Frequently Asked Questions Should I buy or sell Xeris Biopharma stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Biopharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XERS shares. View XERS analyst ratings or view top-rated stocks. What is Xeris Biopharma's stock price forecast for 2023? 3 brokerages have issued 1 year price objectives for Xeris Biopharma's stock. Their XERS share price forecasts range from $4.00 to $6.00. On average, they expect the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 77.3% from the stock's current price. View analysts price targets for XERS or view top-rated stocks among Wall Street analysts. How have XERS shares performed in 2023? Xeris Biopharma's stock was trading at $1.33 on January 1st, 2023. Since then, XERS stock has increased by 112.0% and is now trading at $2.82. View the best growth stocks for 2023 here. When is Xeris Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our XERS earnings forecast. How were Xeris Biopharma's earnings last quarter? Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) released its earnings results on Wednesday, March, 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.06. The firm earned $33.14 million during the quarter, compared to analyst estimates of $31.04 million. Xeris Biopharma had a negative trailing twelve-month return on equity of 147.04% and a negative net margin of 64.08%. What ETF holds Xeris Biopharma's stock ? iShares Neuroscience and Healthcare ETF holds 14,729 shares of XERS stock, representing 0.58% of its portfolio. What guidance has Xeris Biopharma issued on next quarter's earnings? Xeris Biopharma updated its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $135.00 million-$165.00 million, compared to the consensus revenue estimate of $146.90 million. What other stocks do shareholders of Xeris Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Biopharma investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), Cogent Biosciences (UMRX) and Organigram (OGI). When did Xeris Biopharma IPO? (XERS) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager. What is Xeris Biopharma's stock symbol? Xeris Biopharma trades on the NASDAQ under the ticker symbol "XERS." Who are Xeris Biopharma's major shareholders? Xeris Biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Stonepine Capital Management LLC (6.38%), BlackRock Inc. (6.21%), Geode Capital Management LLC (1.87%), State Street Corp (1.68%), JPMorgan Chase & Co. (0.57%) and Deltec Asset Management LLC (0.46%). Insiders that own company stock include Paul R Edick and Steven Prestrelski. View institutional ownership trends. How do I buy shares of Xeris Biopharma? Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Xeris Biopharma's stock price today? One share of XERS stock can currently be purchased for approximately $2.82. How much money does Xeris Biopharma make? Xeris Biopharma (NASDAQ:XERS) has a market capitalization of $382.19 million and generates $110.25 million in revenue each year. The company earns $-94,660,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. How many employees does Xeris Biopharma have? The company employs 294 workers across the globe. How can I contact Xeris Biopharma? Xeris Biopharma's mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The official website for the company is www.xerispharma.com. The company can be reached via phone at (844) 445-5704 or via email at ir@xerispharma.com. This page (NASDAQ:XERS) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.